Further understanding of the biological functions implicated may pave the way for SFRP5 to serve as a promising novel therapeutic target in the treatment of obesity, T2DM, and other metabolic diseases. The gene discussed is SFRP5; the disease is obesity due to melanocortin 4 receptor deficiency.